Print this page
lung
-
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With
Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Protocol: 032404Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Protocol: 032405Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Randomized Phase 2 Platform Study to Evaluate Cemiplimab plus Chemotherapy vs. Cemiplimab plus Chemotherapy plus Other Cancer Treatments for the Perioperative treatment of Patients with Resectable Non-Small Cell Lung Cancer.
Protocol: 032407Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
A Phase 2b, Open-Label, Two-Cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Protocol: 032409Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients
Protocol: 032410Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Pilot Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy (PORT) for Minimal Residual Disease (MRD) for Lung Cancer: the MRD-PORT Trial
Protocol: 032411Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Protocol: 032501Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy.
Protocol: 042201Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants with HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer.
Protocol: 042412Principal Investigator:
- Mridula A George
Applicable Disease Sites: Breast -
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804Principal Investigator:
- Eugenia Girda
Applicable Disease Sites: Any Site -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies.
Protocol: 052002Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Any Site
Liver
Other Digestive Organ -
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and In Combination with Docetaxel in Subjects with Advanced MTAP-Null Solid Tumors.
Protocol: 052208Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR).
Protocol: 052407Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and
Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.
Protocol: 052410Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site -
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 in Participants with Advanced Solid Tumors
Protocol: 052503Principal Investigator:
- Sanjay Goel
Applicable Disease Sites: Any Site